Recently Added |View More
A Comprehensive Overview of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Tuesday, April 9, 2024 5:30 - 6:30 PM EDT - On the heels of the FDA’s recent approval of AMTAGVI (lifileucel) for unrescectable or metastatic melanoma, join Roswell Park subject matter experts for a comprehensive provider education event.
For Roswell Park’s Cell Therapy Team, Innovation is the Norm
Roswell Park Comprehensive Cancer Center is dedicated to becoming the leading cellular therapy innovation engine in the United States, if not the world, in the next 10 years.
Meet the Team: Shernan Holtan, MD
The newest member of the cellular therapy research team and Chief of the Bone Marrow and Transplantation Service at Roswell Park Comprehensive Cancer Center is eager to continue advancing the field.
Amtagvi, First FDA-Approved Cell Therapy for Solid-Tumor Cancers, Available at Roswell Park
Expanding access to a breakthrough treatment option for patients with metastatic melanoma, Roswell Park Comprehensive Cancer Center has been approved to administer the newly FDA-approved tumor-infiltrating lymphocyte (TIL) therapy Amtagvi.
Roswell Park Comprehensive Cancer Center has made it our mission to assemble the beset minds in cellular therapy research and patient care.
Roswell Park Experts Present Latest Discoveries in Stem Cell Transplantation, Cellular Therapy
The Chief of Myeloma at Roswell Park Comprehensive Cancer Center will deliver the latest findings of the CARTITUDE-2 clinical trial at the 2024 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy.
This site is intended for healthcare professionals